With a $600M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development.
We have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope.
While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio.
We can lead or join a syndicate of investors and will seek board representation commensurate with our investment.
Areas of focus
Our investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines.
We also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development
Advantages of working with us
- Pfizer Ventures is an active investor, working with management to develop product strategy and shareholder value.
- We bring a pharmaceutical perspective and have the potential to utilize our internal networks and expertise.
- We have a streamlined approval process for investment decisions.
- All investments have the potential for a business relationship with Pfizer.